PDS Biotechnology (Germany) Performance
| EU6 Stock | EUR 1.67 0.09 5.70% |
The company holds a Beta of 0.0413, which implies not very significant fluctuations relative to the market. As returns on the market increase, PDS Biotechnology's returns are expected to increase less than the market. However, during the bear market, the loss of holding PDS Biotechnology is expected to be smaller as well. At this point, PDS Biotechnology Corp has a negative expected return of -1.03%. Please make sure to check PDS Biotechnology's total risk alpha, potential upside, kurtosis, as well as the relationship between the treynor ratio and skewness , to decide if PDS Biotechnology Corp performance from the past will be repeated at future time.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days PDS Biotechnology Corp has generated negative risk-adjusted returns adding no value to investors with long positions. Despite fragile performance in the last few months, the Stock's basic indicators remain nearly stable which may send shares a bit higher in February 2025. The current disturbance may also be a sign of long-run up-swing for the company stockholders. ...more
| Begin Period Cash Flow | 28.8 M |
PDS |
PDS Biotechnology Relative Risk vs. Return Landscape
If you would invest 334.00 in PDS Biotechnology Corp on October 8, 2024 and sell it today you would lose (167.00) from holding PDS Biotechnology Corp or give up 50.0% of portfolio value over 90 days. PDS Biotechnology Corp is currently producing negative expected returns and takes up 4.8534% volatility of returns over 90 trading days. Put another way, 43% of traded stocks are less volatile than PDS, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
PDS Biotechnology Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for PDS Biotechnology's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as PDS Biotechnology Corp, and traders can use it to determine the average amount a PDS Biotechnology's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.2123
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | EU6 |
Estimated Market Risk
| 4.85 actual daily | 43 57% of assets are more volatile |
Expected Return
| -1.03 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.21 actual daily | 0 Most of other assets perform better |
Based on monthly moving average PDS Biotechnology is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of PDS Biotechnology by adding PDS Biotechnology to a well-diversified portfolio.
PDS Biotechnology Fundamentals Growth
PDS Stock prices reflect investors' perceptions of the future prospects and financial health of PDS Biotechnology, and PDS Biotechnology fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on PDS Stock performance.
| Return On Equity | -0.49 | |||
| Return On Asset | -0.25 | |||
| Current Valuation | 189.69 M | |||
| Shares Outstanding | 28.89 M | |||
| Price To Earning | 23.42 X | |||
| Price To Book | 5.63 X | |||
| EBITDA | (21.43 M) | |||
| Cash And Equivalents | 74.75 M | |||
| Cash Per Share | 2.63 X | |||
| Total Debt | 552.98 K | |||
| Debt To Equity | 0.01 % | |||
| Book Value Per Share | 1.65 X | |||
| Cash Flow From Operations | (12.49 M) | |||
| Earnings Per Share | (0.91) X | |||
| Total Asset | 67.2 M | |||
About PDS Biotechnology Performance
By analyzing PDS Biotechnology's fundamental ratios, stakeholders can gain valuable insights into PDS Biotechnology's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if PDS Biotechnology has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if PDS Biotechnology has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. PDS Biotechnology Corporation was founded in 2005 and is based in Florham Park, New Jersey. PDS BIOTECHNOLOGY operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange. It employs 15 people.Things to note about PDS Biotechnology Corp performance evaluation
Checking the ongoing alerts about PDS Biotechnology for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for PDS Biotechnology Corp help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| PDS Biotechnology generated a negative expected return over the last 90 days | |
| PDS Biotechnology may become a speculative penny stock | |
| PDS Biotechnology has high historical volatility and very poor performance | |
| PDS Biotechnology has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (16.92 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| PDS Biotechnology Corp has accumulated about 74.75 M in cash with (12.49 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.63, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 14.0% of the company shares are held by company insiders |
- Analyzing PDS Biotechnology's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether PDS Biotechnology's stock is overvalued or undervalued compared to its peers.
- Examining PDS Biotechnology's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating PDS Biotechnology's management team can have a significant impact on its success or failure. Reviewing the track record and experience of PDS Biotechnology's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of PDS Biotechnology's stock. These opinions can provide insight into PDS Biotechnology's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for PDS Stock analysis
When running PDS Biotechnology's price analysis, check to measure PDS Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PDS Biotechnology is operating at the current time. Most of PDS Biotechnology's value examination focuses on studying past and present price action to predict the probability of PDS Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PDS Biotechnology's price. Additionally, you may evaluate how the addition of PDS Biotechnology to your portfolios can decrease your overall portfolio volatility.
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine |